Work

Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine.

Year: 2018

Type: article

Abstract: Lu-PSMA I&T) have a favorable dosimetry and convincing therapeutic response. However, ~30% of patients were found to be short or non-responders and dose escalation was severely limited by chronic hematological toxicity. Such limitations could be better overcome by targeted alpha therapy (TAT) which has the potential to bring a paradigm shift in treatment of mCRPCa patients. This concise review presents an overview of the successes and challenges currently faced in TAT of mCRPCa using radiolabeled PSMA inhibitors. The preclinical and clinical data reported to date are quite promising, and it is expected that this therapeutic modality will play a pivotal role in advanced stage PCa management in the foreseeable future.

Source: Europe PMC (PubMed Central)

Authors: Rubel Chakravarty, Cerise M Siamof, Ashutosh Dash, Weibo Cai

Institutions: Bhabha Atomic Research Centre, Homi Bhabha National Institute, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute

Awards: Novel Combination Therapy for Prostate Cancer, UW Comprehensive Cancer Center Support